| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $101.6M | +59.3% |
| SG&A Expense | $49.3M | +33.1% |
| Operating Income | -$150.9M | -49.7% |
| Income Tax | $1K | +0.0% |
| Net Income | -$110.0M | -28.0% |
| EPS (Basic) | -$1.01 | -11.0% |
| EPS (Diluted) | -$1.01 | -11.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $26.7M | -51.9% |
| Current Assets | $907.2M | +147.0% |
| Total Assets | $908.3M | +146.5% |
| Current Liabilities | $27.4M | +43.3% |
| Total Liabilities | $28.0M | +39.7% |
| Stockholders' Equity | $880.3M | +152.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$87.8M | -19.6% |
| Investing Cash Flow | -$553.4M | -209.0% |
| Financing Cash Flow | $612.5M | +125.7% |